Outer membrane vesicle vaccines

•OMV constitute an emerging platform for vaccine development.•Simplicity of manufacture make OMV an attractive technology for affordable vaccines.•More clinical studies will help elucidation of OMV mechanism of action.•Genetic engineering permits OMV modification resulting in enhanced applicability....

Full description

Saved in:
Bibliographic Details
Published inSeminars in immunology Vol. 50; p. 101433
Main Authors Micoli, Francesca, MacLennan, Calman A.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2020
Subjects
Animals
Bacterial diseases
Bacterial Outer Membrane - immunology
Bacterial Vaccines - immunology
Genetic Engineering
GMMA
Humans
Immunity, Heterologous
Immunogenicity, Vaccine
Meningococcal Infections - immunology
Neisseria meningitidis - physiology
OMV
Outer membrane vesicles
Vaccines
glyOMV
MHC
Outer membrane vesicles
Vaccines
LPS
mdOMV
IFN
PAMP
PRR
APC
Bacterial diseases
OMV
nOMV
dOMV
GMMA
TLR
DC
Online AccessGet full text

Cover

More Information
Summary:•OMV constitute an emerging platform for vaccine development.•Simplicity of manufacture make OMV an attractive technology for affordable vaccines.•More clinical studies will help elucidation of OMV mechanism of action.•Genetic engineering permits OMV modification resulting in enhanced applicability. Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1044-5323
1096-3618
1096-3618
DOI:10.1016/j.smim.2020.101433